TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9591517
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day tolcapone
Study: 788768
Drug: Antibiotic/corticosteroid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic/corticosteroid combination
Study: 2463912
Drug: N,N dimethylglycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N,N dimethylglycine (DMG) 300 mg/day for the first 14 days, then 600 mg/day
Study: 26674631
Drug: Average daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average daily moderate-to-vigorous physical activity (MVPA)
Study: 22024518
Drug: TMC435 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 25 mg
Study: 22024518
Drug: TMC435 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 75 mg
Study: 22024518
Drug: TMC435 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 200 mg
Study: 22024518
Drug: TMC435 (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC435 (75, 150, or 200 mg) in treatment-experienced patients
Study: 22024518
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in treatment-experienced patients
Study: 12779258
Drug: Fractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated radiation therapy with a linear accelerator
Study: 9071624
Drug: Topical bifonazole-urea
Normalized name: bifonazole / urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bifonazole-urea ointment alone
Study: 9071624
Drug: Topical bifonazole-urea
Normalized name: bifonazole / urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bifonazole-urea ointment combined with oral griseofulvin 500 mg
Study: 9071624
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral treatment)
Study: 8219113
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose tobramycin (5 mg/kg per day) plus ceftriaxone (2 g/day) (C + T)
Study: 8219113
Drug: Tobramycin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1.5 mg/kg, every 8 h) plus azlocillin (4 g, every 6 h) (A + T)
Study: 2412051
Drug: Ketanserin (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (chronic treatment for 3 months)
Study: 29477133
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and exercise therapy
Study: 29477133
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound and exercise therapy
Study: 26654350
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg amoxicillin and 500 mg metronidazole three times per day for 7 days during the non-surgical treatment phase (T1)
Study: 26654350
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered during the surgical phase (T2)
Study: 25277807
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (placebo group)
Study: 18578178
Drug: Preparation at
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation at 15 minutes after cementation
Study: 18578178
Drug: Preparation at
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation at 24 hours after cementation
Study: 12431867
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) coupled with Bayesian forecasting (D(a))
Study: 6355617
Drug: Furosemide (F)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide (F) 40 mg daily for 3 days
Study: 6355617
Drug: Captopril (C)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (C) 25 mg . 6 hr-1 with Furosemide (F)
Study: 17900460
Drug: Aspirin prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin prescription
Study: 15671918
Drug: ACEI or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI or ARB (angiotensin converting enzyme inhibitor or angiotensin receptor blocker)
Study: 15671918
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or reference drug (beta-blocker or diuretic)
Study: 12571548
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 1 week
Study: 9506593
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with combined streptokinase and tissue plasminogen activator
Study: 3287912
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg once daily for the first two days followed by 20 mg once daily for the remainder of the study (14 days, minimum 7 days, maximum 28 days)
Study: 3287912
Drug: Aspirin 4
Normalized name: aspirin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 4 g per day for the duration of the study
Study: 3287912
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for two days followed by 250 mg in the morning and 500 mg in the evening thereafter
Study: 3287912
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg three times per day for two days and 25 mg three times per day thereafter
Study: 9287260
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for two weeks (n = 27)
Study: 9287260
Drug: De‐Nol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: De‐Nol 240 mg b.d. for four weeks, metronidazole 400 mg t.d.s. and amoxicillin 500 mg t.d.s. for one week (n = 26)
Study: 9287260
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. and amoxicillin 500 mg t.d.s. for two weeks (n = 26)
Study: 9287260
Drug: Traditional 'triple'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional 'triple' therapy with bismuth and two antibiotics
Study: 8320401
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy with dietary adherence support from dietitians
Study: 3549320
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg once daily + Ibuprofen 400 mg t.i.d. for 4 weeks
Study: 3549320
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg once daily + Diclofenac 25 mg t.i.d. for 4 weeks
Study: 3549320
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg once daily + Sulindac 200 mg b.i.d. for 4 weeks
Study: 20575298
Drug: Guo's Maqian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guo's Maqian decoction (200 ml, twice daily for 8 weeks, followed by Guokangning capsule (0.44 g per capsule, 2 capsules, three times daily for 4 weeks))
Study: 20575298
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment including calcium supplementation and herb decoction
Study: 11583826
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active anti-retroviral therapy
Study: 18669951
Drug: Other factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other factors (e.g., reduced body mass index, suboptimal nutrition, anti-retroviral drugs)
Study: 12891224
Drug: Oxcarbazepine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (30 to 46 mg/kg/day, given twice daily)
Study: 10566573
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg, titrated to 20 mg if necessary
Study: 10566573
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg, titrated to 20 mg if necessary
Study: 1809994
Drug: Lubor cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubor cream
Study: 1809994
Drug: Ketonal cream
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketonal cream
Study: 6340000
Drug: Fosfolip (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfolip (calcium salt of phosphorylcholine chloride with pantethine) 3 capsules a day
Study: 31260089
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) adjunctive therapy (400‐1200 mg once daily)
Study: 31260089
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) adjunctive therapy
Study: 31260089
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) monotherapy (1200‐1600 mg once daily)
Study: 29579102
Drug: Pills rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills rich in n‐3 PUFA
Study: 27980393
Drug: Paracetamol (APAP)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (APAP) 2 g
Study: 24172656
Drug: Physiotherapy-led exercise
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy-led exercise program (7 exercises daily for 12 weeks)
Study: 24172656
Drug: Dexamethasone injection
Normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone injection followed by daily calf stretching
Study: 20716080
Drug: Bupivacaine-tramadol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-tramadol (1 mg x kg(‐1))
Study: 17720116
Drug: Ultrasound-guided facet
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided facet joint injections
Study: 17720116
Drug: CT-controlled facet
Normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-controlled facet joint injections
Study: 12087139
Drug: lopinavir-ritonavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir-ritonavir (400 mg of lopinavir plus 100 mg of ritonavir twice daily)
Study: 12087139
Drug: nelfinavir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir (750 mg three times daily)
Study: 10215095
Drug: Complete forebrain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete forebrain commissurotomy (L.B.)
Study: 30370532
Drug: Prolonged exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exercise training (12-week program: resistance exercise twice per week, high intensity interval training once per week)
Study: 23871417
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² every 21 days, intravenously) with Atrasentan (10 mg/day, orally)
Study: 23871417
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m² every 21 days, intravenously) with Placebo
Study: 21825080
Drug: 17.5 mg
Normalized name: acitretin 17.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.5 mg once-weekly risedronate
Study: 21825080
Drug: Placebo (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (combined with daily 1000 IU of ergocalciferol)
Study: 17080507
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg IR formulation)
Study: 15809368
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin to reduce LDL to <80 mg/dL (n=96)
Study: 15809368
Drug: Intensive atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive atorvastatin to reduce LDL to <80 mg/dL plus antioxidant vitamins C (1000 mg/d) and E (800 mg/d) (n=101)
Study: 15809368
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and low-dose lovastatin to reduce LDL to <130 mg/dL (n=103; control group)
Study: 10211493
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with morphine (acupoint group)
Study: 10211493
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with morphine (control group)
Study: 7628595
Drug: ZDV (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV (500 mg daily) alone
Study: 7628595
Drug: ZDV (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV (500 mg daily) with folinic acid (15 mg daily) and intramuscular vitamin B12 (1000 micrograms monthly)
Study: 7628595
Drug: ZDV (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZDV (500 mg daily) with folinic acid and vitamin B12
Study: 824172
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sublingual isosorbide dinitrate
Study: 31576436
Drug: Levosimendan 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan 0.2 µg/kg/min continuous infusion
Study: 28177480
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with bevacizumab (4 cycles of FEC followed by 4 cycles of docetaxel for HER2-negative tumours in BEVERLY-1; docetaxel and trastuzumab for HER2-positive tumours in BEVERLY-2)
Study: 28177480
Drug: CTC detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC detection at baseline (≥1 CTC/7.5 ml)
Study: 28177480
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pCR after neoadjuvant treatment with no CTC detection at baseline
Study: 28177480
Drug: CEC level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEC level at baseline or variations during treatment
Study: 19401663
Drug: VAP technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAP technique (4 applications of 2 ml lidocaine 2% with oxygen flow of 3 l min(‐1))
Study: 19401663
Drug: STAN technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAN technique (insufflation of 3 l min(‐1) oxygen via nasal probe and two applications of 4 ml of lidocaine 2%)
Study: 10379018
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg, twice daily)
Study: 2202199
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) suppositories, 400 mg bid
Study: 27377616
Drug: Lidocaine/tetracaine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/tetracaine cream
Study: 25251749
Drug: Group phone
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group phone participation (CC)
Study: 19322907
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy (antitumor necrosis factor agents) for patients at highest risk of recurrence
Study: 8006284
Drug: Captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (75 mg daily)
Study: 23758456
Drug: Visible-light curing
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visible-light curing of pulp capping compounds (Groups 1-7)
Study: 23758456
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser irradiation without prior application of a pulp capping compound (Groups 8-10)
Study: 19285304
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion for the first 24 hours after surgery
Study: 11518073
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort (Ze 117; 500 mg extract/day)
Study: 9457399
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous rIL-2 alone
Study: 9457399
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous rIL-2 plus rIFN-alpha
Study: 9457399
Drug: Moderate-dose outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose outpatient subcutaneous rIL-2 plus rIFN-alpha
Study: 2905387
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage chlorthalidone
Study: 27479536
Drug: Next-step treatment
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-step treatment for MDD after failing initial antidepressant trial
Study: 27479536
Drug: Next-step treatment
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-step treatment for MDD
Study: 25799445
Drug: Rapid palatal
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid palatal expansion (RPE) and facial mask (FM) therapy
Study: 21083927
Drug: Genotype-guided dosing
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided dosing (warfarin therapy based on algorithms using clinical information and genotypes for polymorphisms in CYP2C9 and VKORC1)
Study: 21083927
Drug: Clinical-guided dosing
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical-guided dosing (warfarin therapy based on algorithms using only clinical information)
Study: 16369994
Drug: Tamoxifen or
Normalized name: tamoxifen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen or toremifene alone or in combination with chemotherapy (either concurrently or sequentially)
Study: 16369994
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy alone (tamoxifen or toremifene)
Study: 16369994
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy or beyond 3 months after completing chemotherapy
Study: 1512327
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy (5,000 U bolus followed by 1,000 U/h continuous infusion)
Study: 1512327
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy (optimal anticoagulation)
Study: 1512327
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy (suboptimal anticoagulation)
Study: 1512327
Drug: Heparin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin therapy (inadequate anticoagulation)
Study: 6527973
Drug: 2.5mg intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg intravenous nicardipine
Study: 6527973
Drug: 10mg intravenous
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg intravenous nicardipine
Study: 30442501
Drug: dinutuximab beta
Normalized name: dinutuximab beta
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dinutuximab beta with subcutaneous IL-2
Study: 25180702
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise program (15-20 minutes, up to 6 times weekly for 12 months)
Study: 22160145
Drug: Darunavir/ritonavir triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir triple therapy
Study: 20813583
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (maximum 3mg/24h)
Study: 17430326
Drug: Granisetron-dexamethasone combination
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron-dexamethasone combination (granisetron 40 microg/kg and dexamethasone 150 microg/kg)
Study: 15478386
Drug: Active cough
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active cough treatment
Study: 9506736
Drug: Suppressive doses
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive doses of L‐T4
Study: 30704923
Drug: Eltrombopag 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 200 mg (100 mg for east Asians) once daily during induction chemotherapy
Study: 28641384
Drug: Lupron® injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron® injections (7.5 mg)
Study: 28641384
Drug: Lupron and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupron and testosterone (L+T) replacement for 49 days
Study: 24403557
Drug: JS7 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS7 DNA vaccine and MVA/HIV62B (DDMM regimen)
Study: 22275160
Drug: Fasudil 40
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 40 mg
Study: 22275160
Drug: Fasudil 80
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 80 mg
Study: 22275160
Drug: Fasudil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (40 mg or 80 mg)
Study: 7602350
Drug: Ifosfamide 5
Normalized name: ifosfamide 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 5 g/m2 by 24-hour continuous intravenous infusion with mesna on day 1, carboplatin 300 mg/m2 intravenously on day 1, etoposide 50 mg/m2 orally on days 1 to 21 every 4 weeks (schedule I)
Study: 7602350
Drug: Ifosfamide 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide 3.75 g/m2 IV on day 1, carboplatin 300 mg/m2 IV on day 1, etoposide 50 mg orally on days 1 to 14 (schedule II)
Study: 7602350
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (ICE regimen)
Study: 2085990
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 grams, single dose)
Study: 2085990
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg b.i.d. for 7 days)